221 related articles for article (PubMed ID: 34717237)
1. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
3. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.
Pulya S; Patel T; Paul M; Adhikari N; Banerjee S; Routholla G; Biswas S; Jha T; Ghosh B
Eur J Med Chem; 2022 Aug; 238():114470. PubMed ID: 35635949
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
11. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
[TBL] [Abstract][Full Text] [Related]
12. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
[TBL] [Abstract][Full Text] [Related]
13. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
14. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response.
Wu WC; Liu YM; Lin MH; Liao YH; Lai MJ; Chuang HY; Hung TY; Chen CH; Liou JP
Eur J Med Chem; 2020 Apr; 192():112158. PubMed ID: 32171161
[TBL] [Abstract][Full Text] [Related]
16. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
Mao PT; He WB; Mai X; Feng LH; Li N; Liao YJ; Zhu CS; Li J; Chen T; Liu SH; Zhang QM; He L
Bioorg Med Chem; 2022 Feb; 56():116599. PubMed ID: 35041998
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
19. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.
Yang F; Han L; Zhao N; Yang Y; Ge D; Zhang H; Chen Y
Future Med Chem; 2020 Apr; 12(8):655-672. PubMed ID: 32202140
[No Abstract] [Full Text] [Related]
[Next] [New Search]